CYTOO

About

CYTOO is a Contract Research Organization (CRO) based in Grenoble, France, specializing in advanced cellular models and assay development for high-content screening in drug discovery. The company focuses on modeling human muscle pathologies and related diseases, addressing muscular dysfunction across various conditions, including rare neuromuscular diseases, obesity, diabetes, and cardiomyopathies. CYTOO's proprietary MyoScreen™ platform offers tailored in vitro discovery services for target identification, compound screening, and GMP-compliant potency assays. The company provides advanced cellular models, including human iPS-derived cardiomyocytes and robust 3D spheroid models, along with assay development for applications like muscular atrophy and drug profiling. Additionally, CYTOO offers micropatterned products designed for cell-based assays to promote mature phenotypes in various models. The company collaborates with Asklepios BioPharmaceutical, Inc. to select a gene therapy candidate for a rare muscle disorder, targeting clients in the biomedical research sector, particularly biotech and pharma firms involved in therapeutic R&D for muscle disorders and gene therapies.